scPharmaceuticals, Inc. $SCPH Stake Lowered by Deutsche Bank AG

Key Points

• Deutsche Bank AG reduced its position in scPharmaceuticals, Inc. by 61.7%, now holding approximately 0.06% of the company.
• The company reported a quarterly loss of ($0.34) earnings per share, missing estimates, despite revenues of $16.04 million.
• scPharmaceuticals has received several diminished ratings from analysts, with a consensus rating of "Hold" and a price target of $12.00.

Deutsche Bank AG trimmed its position in shares of scPharmaceuticals, Inc. (NASDAQ:SCPH - Free Report) by 61.7% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 31,603 shares of the company's stock after selling 50,885 shares during the period. Deutsche Bank AG owned approximately 0.06% of scPharmaceuticals worth $83,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the stock. Chicago Partners Investment Group LLC bought a new position in shares of scPharmaceuticals during the first quarter worth about $31,000. Assenagon Asset Management S.A. bought a new position in scPharmaceuticals in the first quarter worth about $33,000. Legato Capital Management LLC lifted its holdings in scPharmaceuticals by 48.1% in the first quarter. Legato Capital Management LLC now owns 15,275 shares of the company's stock worth $40,000 after acquiring an additional 4,961 shares during the last quarter. Perkins Capital Management Inc. lifted its holdings in scPharmaceuticals by 41.0% in the first quarter. Perkins Capital Management Inc. now owns 17,200 shares of the company's stock worth $45,000 after acquiring an additional 5,000 shares during the last quarter. Finally, ProShare Advisors LLC bought a new position in scPharmaceuticals in the fourth quarter worth about $48,000. 89.52% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. Maxim Group cut shares of scPharmaceuticals from a "buy" rating to a "hold" rating in a report on Monday, August 25th. Wall Street Zen upgraded shares of scPharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, August 9th. HC Wainwright lowered shares of scPharmaceuticals from a "strong-buy" rating to a "hold" rating and set a $5.35 price target on the stock. in a research note on Friday, August 29th. Finally, Craig Hallum lowered shares of scPharmaceuticals from a "buy" rating to a "hold" rating and set a $6.00 price target on the stock. in a research note on Monday, August 25th. Three analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $7.78.

scPharmaceuticals Price Performance

scPharmaceuticals stock traded up $0.01 during mid-day trading on Wednesday, hitting $5.52. The company's stock had a trading volume of 935,295 shares, compared to its average volume of 2,047,256. The company has a quick ratio of 3.14, a current ratio of 3.85 and a debt-to-equity ratio of 3.86. The stock has a market capitalization of $294.22 million, a P/E ratio of -3.05 and a beta of 0.35. scPharmaceuticals, Inc. has a twelve month low of $1.94 and a twelve month high of $6.28. The stock's fifty day moving average price is $4.84 and its two-hundred day moving average price is $3.68.

scPharmaceuticals (NASDAQ:SCPH - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.04). scPharmaceuticals had a negative return on equity of 1,647.86% and a negative net margin of 183.55%.The business had revenue of $16.04 million during the quarter, compared to analyst estimates of $15.41 million. Research analysts forecast that scPharmaceuticals, Inc. will post -1.53 earnings per share for the current year.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.